Relapsing multiple sclerosis is a form of the disease where patients
experience a periodic worsening of symptoms. Sensory and motor loss of
function leads to increased disability, and patients can need a cane or
A signature of the disease is the appearance of lesions in
the brain, which are linked to inflammation and can show up through MRI
detection during active periods of multiple sclerosis relapse.
‘Ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple sclerosis relapse.’
Results from a new Phase 3 study conducted by the Celgene Corporation
demonstrate that ozanimod, a drug candidate originally discovered and
optimized at The Scripps Research Institute (TSRI), can reduce the
frequency of multiple sclerosis relapse.Ozanimod, discovered by TSRI Professors Hugh Rosen and Ed Roberts
and their laboratories, acts as a sphingosine 1-phosphate 1 (S1PR1)
receptor agonist - modulating S1PR1 signaling and blocking sources of
Rosen and Roberts went on to co-found Receptos, a clinical
stage biopharmaceutical company that took ozanimod into Phase 1, 2 and 3
clinical trials and was then acquired by Celgene. Ozanimod is the first
New Chemical Entity discovered from a starting point in the NIH Common
Fund Molecular Libraries Initiative to reach and succeed in advanced
As reported by Celgene, results from the randomized, Phase 3,
double-blind, double-dummy, active-controlled SUNBEAM study among 1,346
participants show that ozanimod met its primary endpoint in reducing
annualized relapse rate (ARR) of relapsing multiple sclerosis, compared
with an alternate drug treatment called weekly interferon (IFN) β-1a
Administered at doses of both 1 mg and 0.5 mg, ozanimod demonstrated
statistically significant and clinically meaningful improvements,
compared to Avonex®, for the primary endpoint of ARR and the measured
secondary endpoints of the number of MRI-detected lesions and the number
of new or enlarging "T2" MRI lesions at after a year of treatment.
"It is exciting and rewarding to see the results of this new Phase 3
trial, which confirm the safety profile from the two-year extension
data from the Phase 2 RADIANCE study and underscore ozanimod's efficacy
in reducing the burden of MS symptoms on patients and their families,"
said Rosen. "We look forward to seeing the full study results, as well
as the results from the Phase 3 study evaluating ozanimod in patients
with ulcerative colitis."
Scientists involved in the trial plan to present the full Phase 3 trial results at an upcoming international scientific meeting.